Cover Image


Advances in Cancer Immunotherapy Report 2014

出版商 BMI Research 商品編碼 321058
出版日期 內容資訊 英文 101 pages
商品交期: 最快1-2個工作天內
Back to Top
癌症免疫療法的進步 Advances in Cancer Immunotherapy Report 2014
出版日期: 2014年12月09日 內容資訊: 英文 101 pages



  • 免疫-癌症市值的預測
  • 美國承認的免疫檢查站抑制劑為何?
  • 大受歡迎的預測免疫療法為何?
  • 進行PD-1/PD-L1 抑制劑臨床開發的企業為何?
  • 在英國被授予「Promising Innovative Medicine(有潛力創新的藥物)」的稱號的癌症疫苗為何?
  • 與Brisol-Myers' Squibb's Yervoy(Ipilimumab)組合進行臨床試驗的免疫療法為何?
  • 以INCB24360聯合治療與Incyte協議開發的企業為何?

Instant access to your report in PDF format through your account library

With immuno-oncology widely expected to revolutionise the treatment of cancer, Espicom has just published Advances in Cancer Immunotherapy 2014.

Reviewing the key players in this field alongside some smaller companies that have made progress in particular areas, this special report provides information on advances in cancer immunotherapy.

‘Advances in Cancer Immunotherapy 2014’ answers key questions such as:

  • What is the immuno-oncology market forecast to be worth by 2018?
  • Which checkpoint inhibitors are approved in the USA?
  • Which immunotherapies are expected to reach blockbuster status in 2016?
  • Which companies have PD-1/PD-L1 inhibitors in clinical development?
  • Which cancer vaccine was awarded the UK's ‘Promising Innovative Medicine' designation in September 2014?
  • Which immunotherapies are in clinical trials in combination with Brisol-Myers' Squibb's Yervoy (ipilimumab)?
  • Which companies have development agreements with Incyte for combinations with INCB24360?

Published by Espicom - experts in the healthcare field for over 30 years, ‘Advances in Cancer Immunotherapy 2014’ brings together a range of often difficult to source information in one single, convenient and comprehensive publication.

Back to Top